Invus — 2023 Investments
2 investments dated 2023 · listed companies and verified rows first · show all
Cyclerion is a biopharmaceutical company developing therapeutics for neuropsychiatric diseases, with a lead candidate (CYC-126) for treatment-resistant depression that pairs anesthetic agents with a personalized biofeedback-driven device.
BiotechDigital HealthMental HealthCambridge, US
William Huyett(Executive Officer)Mark G. Currie(Executive Officer)inOle Isacson(Director)Stephanie Lovell(Director)Marsha Fanucci(Director)George Conrades(Director)
Co-investorsPappas CapitalPolaris Partners
BiotechCambridge, US
Philip Kantoff(Executive Officer, Director)inNeil Bander(Executive Officer, Director)Eric Sullivan(Executive Officer)inAlexander Brown(Executive Officer)in
BoardJake Simson(Director)inTal Zaks(Director)
Co-investorsOrbiMedRA Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.